Unibest

Pharmaceutical intermediates

Upadacitinib Intermediates

8 pharmaceutical intermediates for Upadacitinib. Indication: Arthritis; Ankylosing Spondylitis.

提交项目All intermediates

About Upadacitinib

Originator
AbbVie
Indication
Arthritis; Ankylosing Spondylitis
Approved Date
08/16/2019
DS/DP
01/15/2031

Available intermediates

8 intermediates currently listed for Upadacitinib. Request specifications, documentation or a quotation for any item below.

Upadacitinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate1201187-44-1//
(3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester1428243-26-8//
N-[5-[(4-Methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamic acid ethyl ester1869118-24-0//
N-Tosyl-5-bromo-4,7-diazaindole1201186-54-0//
1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid1869118-25-1//
(3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid1428243-24-6//
8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine1428243-28-0//
5-Bromo-4,7-diazaindole875781-43-4//

Other programs under U

UbrogepantUmbralisib

Building toward Upadacitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →